Despite the irrefutable role of inflammation in psoriasis, a complete knowledge of what immune cells and cytokines are involved during initiation and progression of this skin disease is lacking. Moreover, the complexities of the immune cell network and potential differences between mice and humans have led to translational failures. It is therefore important that we acquire in-depth understanding of what inflammatory players, of the many involved, are crucial, if we wish to develop effective therapies. In 'Bedside to Bench', James Krueger discusses how a subset of T cells, TH17 cells, which release interleukin-17 in humans, seem to be essential for pathogenesis of psoriasis. The interplay between interleukin-17 and other cytokines that may potentially be involved in psoriasis also needs further investigation. Additionally, there are open questions as to what subset of T cells, other than TH17, also produce interleukin-17 and when. In 'Bench to Bedside', Burkhard Becher and Stanislav Pantelyushin examine this issue by looking at a mouse model of skin inflammation that resembles psoriasis in humans. A class of skin-invading innate immune cells called γδ T cells was shown to drive skin inflammation in this model, particularly during the early stages of the disease, suggesting that innate immunity plays an important part in the initiation of psoriasis.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Perera, G.K., Di Meglio, P. & Nestle, F.O. Annu. Rev. Pathol. 7, 385–422 (2012).
Gutcher, I. & Becher, B. J. Clin. Invest. 117, 1119–1127 (2007).
Boyman, O. et al. J. Exp. Med. 199, 731–736 (2004).
Blumberg, H. et al. J. Immunol. 185, 4354–4362 (2010).
Griffiths, C.E.M. et al. N. Engl. J. Med. 362, 118–128 (2010).
Gottlieb, A.B. et al. Br. J. Dermatol. 165, 652–660 (2011).
Hueber, W. et al. Sci. Transl. Med. 2, 52ra72 (2010).
Leonardi, C. et al. N. Engl. J. Med. 366, 1190–1199 (2012).
Papp, K.A. et al. N. Engl. J. Med. 366, 1181–1189 (2012).
Bissonnette, R. et al. J. Am. Acad. Dermatol. 62, 427–436 (2010).
Gilliet, M. et al. Arch. Dermatol. 140, 1490–1495 (2004).
van der Fits, L. et al. J. Immunol. 182, 5836–5845 (2009).
Cai, Y. et al. Immunity 35, 596–610 (2011).
Pantelyushin, S. et al. J. Clin. Invest. 122, 2252–2256 (2012).
Laggner, U. et al. J. Immunol. 187, 2783–2793 (2011).
Guo, L., Junttila, I.S. & Paul, W.E. Trends Immunol. published online, 10.1016/j.it.2012.07.006 (7 September 2012).
Eberl, G. Immunol. Rev. 245, 177–188 (2012).
Antoniu, S.A. Expert Opin. Investig. Drugs 21, 1607–1618 (2012).
The authors declare no competing financial interests.
About this article
Cite this article
Becher, B., Pantelyushin, S. Hiding under the skin: Interleukin-17–producing γδ T cells go under the skin?. Nat Med 18, 1748–1750 (2012). https://doi.org/10.1038/nm.3016
E3 ubiquitin ligase NEDD4L negatively regulates keratinocyte hyperplasia by promoting GP130 degradation
EMBO reports (2021)
Cellular & Molecular Immunology (2020)
Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice
Journal of Clinical Investigation (2020)
Frontiers in Immunology (2020)